Jefferies analyst Chris Howerton, PhD reiterated a Buy rating but lowered his price target on Atara Biotherapeutics (NASDAQ: ATRA) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE